No matches
Pulmonology

The Burden in Patients with CRSwNP and Coexisting Asthma

This video supports improved clinical awareness and encourages comprehensive care strategies for patients living with both CRSwNP and asthma.

Related resources

ERS 2023 | Adult Asthma Symposium: Mini Debate

ERS 2023 | Adult Asthma Symposium: Mini Debate

expert video
ERS 2023 | Adult Asthma Symposium: Panel Discussion

ERS 2023 | Adult Asthma Symposium: Panel Discussion

expert video
ERS 2023 | Advancing Asthma Management Beyond Control

ERS 2023 | Advancing Asthma Management Beyond Control

expert video
ERS 2023 | Assessing Disease Activity to Better Define On-Treatment Clinical Remission in Pediatric Severe Asthma

ERS 2023 | Assessing Disease Activity to Better Define On-Treatment Clinical Remission in Pediatric Severe Asthma

expert video
ERS 2023 | Burden of Underlying Disease in Pediatric Severe Asthma

ERS 2023 | Burden of Underlying Disease in Pediatric Severe Asthma

expert video
ERS 2023 | Evolving Patient Care: From Symptom Control to On-Treatment ​Clinical Remission​

ERS 2023 | Evolving Patient Care: From Symptom Control to On-Treatment ​Clinical Remission​

expert video
ERS 2023 | How Achievable Is Clinical Remission on Biologic Therapy?

ERS 2023 | How Achievable Is Clinical Remission on Biologic Therapy?

expert video
ERS 2023 | On-Therapy Remission in Pediatric Asthma: Where Are We Today?

ERS 2023 | On-Therapy Remission in Pediatric Asthma: Where Are We Today?

expert video
ERS 2023 | Pediatric Asthma Symposium: Patient Case Discussion

ERS 2023 | Pediatric Asthma Symposium: Patient Case Discussion

expert video
ERS 2023 | Progression of Underlying Disease in Pediatric Severe Asthma

ERS 2023 | Progression of Underlying Disease in Pediatric Severe Asthma

expert video
ERS 2023 | Type 2 Biomarkers as Predictive and Prognostic Tools to Guide Management

ERS 2023 | Type 2 Biomarkers as Predictive and Prognostic Tools to Guide Management

expert video
IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective

IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective

expert video
ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

expert video
Type 2 Inflammation Underpins Pediatric Severe Asthma

Type 2 Inflammation Underpins Pediatric Severe Asthma

Infographic
ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

expert video
GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

interactivity
IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

expert video
IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

expert video
IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

expert video
ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?

ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?

Podcast
ADVENT On Air | Loss of Smell in CRSwNP Patients

ADVENT On Air | Loss of Smell in CRSwNP Patients

Podcast
ADVENT On Air | Remission in CRSwNP

ADVENT On Air | Remission in CRSwNP

Podcast
Lung Function Assessment Is a Fundamental Component of Optimal Asthma Care

Lung Function Assessment Is a Fundamental Component of Optimal Asthma Care

videoanimation
How Can Poor Lung Function Impact Asthma Burden in Pediatric Patients?

How Can Poor Lung Function Impact Asthma Burden in Pediatric Patients?

videoanimation
EAACI 2024 Emerging Definitions of Clinical Remission and Achieving Clinical Remission With Biologics for Patients With Asthma

EAACI 2024 Emerging Definitions of Clinical Remission and Achieving Clinical Remission With Biologics for Patients With Asthma

expert video
EAACI 2024 Evolving Perspectives in CRSwNP Patient Care

EAACI 2024 Evolving Perspectives in CRSwNP Patient Care

expert video
ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

Podcast
How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

expert video
Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

expert video
Dr. Giorgio Canonica Regarding Multidisciplinary Approach

Dr. Giorgio Canonica Regarding Multidisciplinary Approach

expert video
Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

expert video
Eosinophils as a Biomarker for Type 2 Asthma

Eosinophils as a Biomarker for Type 2 Asthma

expert video
Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

expert video
COPD and Asthma: What's the Difference and Is There a Link?

COPD and Asthma: What's the Difference and Is There a Link?

interactivity
Connecting Type 2 Inflammation to CRSwNP

Connecting Type 2 Inflammation to CRSwNP

expert video
CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

interactivity
FeNO as a Biomarker for Type 2 Asthma

FeNO as a Biomarker for Type 2 Asthma

expert video
How Can Poor Lung Function Impact Asthma Burden in Adult Patients?

How Can Poor Lung Function Impact Asthma Burden in Adult Patients?

videoanimation
IgE as a Biomarker for Type 2 Asthma

IgE as a Biomarker for Type 2 Asthma

expert video
Monitoring Lung Function Is an Important Aspect of Pediatric Asthma Management

Monitoring Lung Function Is an Important Aspect of Pediatric Asthma Management

interactivity
On-Treatment Clinical Remission in Asthma Patients Case Tool

On-Treatment Clinical Remission in Asthma Patients Case Tool

interactivity
Pediatric Asthma Patient Case Tool: Ash

Pediatric Asthma Patient Case Tool: Ash

interactivity
The Cycle of Inflammation in Adult Asthma

The Cycle of Inflammation in Adult Asthma

interactivity
Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

Infographic
Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

expert video

Learning objectives

  • Explore the pathophysiological link between CRSwNP and asthma, including Type 2 inflammation
  • Understand key considerations for integrated, multidisciplinary management approaches

Description

The video explores the shared inflammatory pathways driving both conditions, the heightened disease burden experienced by patients with comorbid CRSwNP and asthma, and the implications for diagnosis and management.

Tags
coexisting diseasesupper airwayasthmaCRSwNPpatient burdendisease severity
MAT-GLB-2505591 - 1.0 - 10/2025

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: NorwayChange country/region